RxDoctor Payments Data

Brent Anderson, MD

Cardiovascular Disease · Nashville, TNNPI 1255488052

Payments from drug & device makers

$2,026in general payments, 2019–2025

Across 95 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$439
  • Boston Scientific$353
  • Amgen$269
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$249
  • Boehringer Ingelheim$200
  • Paragon 28, Inc.$143
  • plus $372 from 9 others

What the payments were for

  • Food & beverage$2,026100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,026 in reported general payments places this provider in the 45th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$202,243
Medicare patients
1,416
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban276$374,681
Repatha SureclickEvolocumab67$69,581
JardianceEmpagliflozin35$59,721
EntrestoSacubitril/Valsartan39$47,728
XareltoRivaroxaban24$32,216
BrilintaTicagrelor15$17,403
Rosuvastatin Calcium399$6,502
Ezetimibe197$5,194
Atorvastatin Calcium333$4,277
Torsemide123$2,964
Ranolazine ErRanolazine24$2,798
Metoprolol Succinate224$2,796
Olmesartan Medoxomil91$1,983
Potassium Chloride53$1,687
Amlodipine Besylate318$1,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$200$59,72135 claims
NovartisEntresto$439$47,72839 claims
Johnson & JohnsonXarelto$85$32,21624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →